Publications & Presentations

May. 11, 2022

Verve Therapeutics: In Vivo CRISPR Base Editing to Treat ASCVD

TIDES

VERVE-101, GalNAc-LNP

2022

PCSK9

Apr. 29, 2022

Comprehensive approach to evaluate off-target editing for an in vivo liver base editing medicine targeting the PCSK9 gene

Keystone Symposia

VERVE-101

2022

PCSK9

Apr. 04, 2022

An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201

ACC

VERVE-101, VERVE-201

2022

ANGPTL3, PCSK9

Apr. 04, 2022

Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in non-human primates

ACC

VERVE-101, VERVE-201

2022

ANGPTL3, PCSK9

Nov. 09, 2021

In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia

VERVE-201, GalNAc-LNP

2021

ANGPTL3

Sep. 23, 2021

Safety and Durability of VERVE-101

TIDES

VERVE-101

2021

PCSK9

Sep. 23, 2021

Targeted delivery of base editors to hepatocytes in vivo

TIDES

VERVE-201, GalNAc-LNP

2021

ANGPTL3